Format

Send to

Choose Destination
Coron Artery Dis. 2011 Mar;22(1):113-21. doi: 10.1097/01.mca.0000394697.74220.cd.

Adjunctive pharmacologic therapy in percutaneous coronary intervention: part II anticoagulant therapy.

Author information

1
Department of Cardiology, College of Medicine, Kyung Hee University Medical Center, Seoul, Korea.

Abstract

Pharmacological adjuvant therapies to protect against procedure-related thrombotic complication are indispensable during percutaneous coronary intervention. In addition to antiplatelet therapy, use of anticoagulants to prevent acute thrombotic complication during percutaneous coronary intervention is essential. Besides unfractionated heparin (UFH), new anticoagulants have been developed and compared with UFH. Low-molecular weight heparins, direct thrombin inhibitors (e.g. bivalirudin), and recently developed agents such as fondaparinux (a factor Xa inhibitor) provide new alternatives to conventional UFH.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center